Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema

Retina

Volumn 36, Issue 10, 2016, Pages 1986-1996

  Shah, Sanket U ^a   Harless, Ashley ^b   Bleau, Laura ^b   Maturi, Raj K ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWEST EYE INSTITUTE   (United States)

Author keywords

bevacizumab; dexamethasone; diabetic macular edema; optical coherence tomography; sustained release implant; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED DELIVERY SYSTEM; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OFF LABEL DRUG USE; PERSISTENT DIABETIC MACULAR EDEMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; COMPLICATION; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG IMPLANT; FLUORESCENCE ANGIOGRAPHY; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSEUDOPHAKIA; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOPHAKIA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84973884837     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001038     Document Type: Article

References (22)

1. CDC. Centers for Disease Control and Prevention-About Vision Health-Common Eye Disorders-Vision Health Initiative (VHI). http://www.cdc.gov/visionhealth/basic-information/eye-disorders.htm. Accessed on August 16, 2015.
2. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014; 132: 1334-1340.
3. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e35.
4. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
5. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
6. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-1665.
7. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-1203.
8. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
9. Dhoot DS, Pieramici DJ, Nasir M, et al. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond) 2015; 29: 534-541.
10. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122: 375-381.
11. Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment. Ophthalmology 2012; 119: 2312-2318.
12. Maturi RK, Bleau L, Saunders J, et al. A 12-month, singlemasked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with contin. Retina 2015; 35: 1604-1614.
13. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999; 96: 10836-10841.
14. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005; 30: 949-957.
15. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152: 686-694.
16. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-1159.
17. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132.
18. Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914.
19. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843-1851.
20. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7: 1423-1428.
21. Totan Y, Güler E, Güraǧaç FB. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res 2016; 41: 107-113.
22. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121: 2473-2481.